The European Commission opened an in-depth investigation on Thursday 22 July to assess the proposed acquisition of GRAIL by Illumina under the EU Merger Regulation.
Illumina is a global health technologies company, and leading supplier of next generation sequencing (“NGS”) systems for genetic and genomic analysis, which include NGS instruments, consumables and ancillary services. GRAIL is developing cancer detection tests relying on NGS systems.
The Commission is concerned about the...